Placeholder Banner

BIO Comments on SEC Proposed Proxy Amendments

February 3, 2020

In comments to the Securities and Exchange Commission (SEC), BIO applauds the SEC for taking a proactive approach in amending the exemptions from the proxy rules for proxy voting. If adopted, the proposal will significantly improve proxy firm transparency without sacrificing investor protection. 

Download Full Comments Below
Final Comments on SEC Proposed Proxy Amendments
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…